Penetration, diffusion, and uptake of recombinant human α-L-iduronidase after intraventricular injection into the rat brain

Molecular Genetics and Metabolism

Volumn 86, Issue 1-2, 2005, Pages 141-149

  Belichenko, P V ^a   Dickson, P I ^b   Passage, M ^b   Jungles, S ^c   Mobley, W C ^a   Kakkis, E D ^b,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c BIOMARIN PHARMACEUTICAL INC   (United States)

Author keywords

L Iduronidase; Brain; Hurler; Lysosomal storage disease; Mucopolysaccharidosis; Rat; Scheie

Indexed keywords

RECOMBINANT ENZYME; RECOMBINANT HUMAN ALPHA LEVO IDURONIDASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN NERVE CELL; BRAIN TISSUE; CELL VACUOLE; CEREBROSPINAL FLUID; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG UPTAKE; ENZYME ACTIVITY; ENZYME ASSAY; GLIA CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INJECTION; LATERAL BRAIN VENTRICLE; LYSOSOME; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; QUANTITATIVE ANALYSIS; RAT; STAINING; STEREOTAXIS;

ANIMALS; DIFFUSION; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IDURONIDASE; INJECTIONS, INTRAVENTRICULAR; MALE; MICROSCOPY, CONFOCAL; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS;

EID: 26244447178     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2005.04.013     Document Type: Article

References (37)

1. E.F. Neufeld, and J. Muenzer The mucopolysaccharidoses C.R. Scriver A.L. Beaudet D. Valle W.S. Sly The metabolic and molecular bases of inherited disease 2001 McGraw-Hill New York 3421 3452
2. J.E. Wraith, L.A. Clarke, M. Beck, E.H. Kolodny, G.M. Pastores, J. Muenzer, D.M. Rapoport, K.I. Berger, S.J. Swiedler, E.D. Kakkis, T. Braakman, E. Chadbourne, K. Walton-Bowen, and G.F. Cox Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-l-iduronidase (laronidase) J. Pediatr. 144 2004 581 588
3. E.D. Kakkis, E. Schuchman, X. He, Q. Wan, S. Kania, S. Wiemelt, C.W. Hasson, T. O'Malley, M.A. Weil, G.A. Aguirre, D.E. Brown, and M.E. Haskins Enzyme replacement therapy in feline mucopolysaccharidosis I Mol. Genet. Metab. 72 2001 199 208
4. R.M. Shull, E.D. Kakkis, M.F. McEntee, S.A. Kania, A.J. Jonas, and E.F. Neufeld Enzyme replacement in a canine model of Hurler syndrome Proc. Natl. Acad. Sci. USA 91 1994 12937 12941
5. E.D. Kakkis, J. Muenzer, G.E. Tiller, L. Waber, J. Belmont, M. Passage, B. Izykowski, J. Phillips, R. Doroshow, I. Walot, R. Hoft, and E.F. Neufeld Enzyme replacement therapy in mucopolysaccharidosis I New Engl. J. Med. 344 2001 182 188
6. G.C. Zirzow, O.A. Sanchez, G.J. Murray, R.O. Brady, and E.H. Oldfield Delivery, distribution, and neuronal uptake of exogenous mannose-terminal glucocerebrosidase in the intact rat brain Neurochem. Res. 24 1999 301 305
7. J.F. Hamilton, P.F. Morrison, M.Y. Chen, J. Harvey-White, R.S. Pernaute, H. Phillips, E. Oldfield, and K.S. Bankiewicz Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotropic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin Exp. Neurol. 168 2001 155 161
8. W.M. Pardridge Drug and gene delivery to the brain: the vascular route Neuron 36 2002 555 558
9. W.S. Prince, L.M. McCormick, D.J. Wendt, P.A. Fitzpatrick, K.L. Schwartz, A.I. Aguilera, V. Koppaka, T.M. Christianson, M.C. Vellard, N. Pavloff, J.F. Lemontt, M. Qin, C.M. Starr, G. Bu, and T.C. Zankel Lipoprotein receptor binding, cellular uptake, and lysosomal delivery of fusions between the receptor-associated protein (RAP) and α-l-iduronidase or acid α-glucosidase J. Biol. Chem. 279 2004 35037 35046
10. M. Demeule, J. Poirier, J. Jodoin, Y. Bertrand, R.R. Desrosiers, C. Dagenais, T. Nguyen, J. Lanthier, R. Gabathuler, M. Kennard, W.A. Jefferies, D. Karkan, S. Tsai, L. Fenart, R. Cecchelli, and R. Béliveau High transcytosis of melanotransferrin (P97) across the blood-brain barrier J. Neurochem. 83 2002 924 933
11. G. Nilaver, L.L. Muldoon, R.A. Kroll, M.A. Pagel, X.O. Breakefield, B.L. Davidson, and E.A. Neuwelt Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption Proc. Natl. Acad. Sci. USA 92 1995 9829 9833
12. P.P. Young, C.R. Fantz, and M.S. Sands VEGF disrupts the neonatal blood-brain barrier and increases life span after non-ablative BMT in a murine model of congenital neurodegeneration caused by a lysosomal enzyme deficiency Exp. Neurol. 188 2004 104 114
13. R.H. Bobo, D.W. Laske, A. Akbasak, P.F. Morrison, R.L. Dedrick, and E.H. Oldfield Convection-enhanced delivery of macromolecules in the brain Proc. Natl. Acad. Sci. USA 91 1994 2076 2080
14. D.W. Laske, R.J. Youle, and E.H. Oldfield Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors Nat. Med. 3 1997 1362 1368
15. J.H. Sampson, G. Akabani, G.E. Archer, D.D. Bigner, M.S. Berger, A.H. Friedman, H.S. Friedman, J.E. Herndon II, S. Kunwar, S. Marcus, R.E. McLendon, A. Paolino, K. Penne, J. Provenzale, J. Quinn, D.A. Reardon, J. Rich, T. Stenzel, S. Tourt-Uhlig, C. Wikstrand, T. Wong, R. Williams, F. Yuan, M.R. Zalutsky, and I. Pastan Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors J. Neuro-Oncol. 65 2003 27 35
16. B. Bembi, M. Zanatta, R. Boscolo, M. Bottega, V. Forleo, M. Carrozi, Enzyme replacement therapy in acute neuronopathic Gaucher's patient, Abstr. VI Int. Congress on Inborn Errors of Metabolism, Milano, Italy, May 27, 1994.
17. D.M. Lieberman, D.W. Laske, P.F. Morrison, K.S. Bankiewicz, and E.H. Oldfield Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion J. Neurosurg. 82 1995 1021 1029
18. S.S. Gill, N.K. Patel, G.R. Hotton, K. O'Sullivan, R. McCarter, M. Bunnage, D.J. Brooks, C.N. Svendsen, and P. Heywood Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease Nat. Med. 9 2003 589 595
19. A.I. Brooks, C.S. Stein, S.M. Hughes, J. Heth, P.M. McCray Jr., S.L. Sauter, J.C. Johnston, D.A. Cory-Slechta, H.J. Federoff, and B.L. Davidson Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors Proc. Natl. Acad. Sci. USA 99 2002 6216 6221
20. W.A. Frisella, L.H. O'Conner, C.A. Vogler, M. Roberts, S. Walkley, B. Levy, T.M. Daly, and M.S. Sands Intracranial injection of recombinant adeno-associated virus improves cognitive function in a murine model of mucopolysaccharidosis type VII Mol. Ther. 3 2001 351 358
21. A. Consiglio, A. Quattrini, S. Martino, J.C. Bensadoun, D. Dolcetta, A. Trojani, G. Benaglia, S. Marchesini, V. Cestari, A. Oliverio, C. Bordignon, and L. Naldini In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice Nat. Med. 7 2001 310 316
22. Y. Eto, J.-S. Shen, X.-L. Meng, and T. Ohashi Treatment of lysosomal storage disorders: cell therapy and gene therapy J. Inherit. Metab. Dis. 27 2004 411 415
23. M. Shimamura, N. Sato, Y. Taniyama, S. Yamamoto, M. Endoh, H. Kurinami, M. Aoki, T. Ogihara, Y. Kaneda, and R. Morishita Development of efficient plasmid DNA transfer into adult rat central nervous system using microbubble-enhanced ultrasound Gene Ther. 11 2004 1532 1539
24. N. Desmaris, L. Verot, J.P. Puech, C. Caillaud, M.T. Vanier, and J.M. Heard Prevention of neuropathology in the mouse model of Hurler syndrome Ann. Neurol. 56 2004 68 76
25. N. Déglon, and P. Hantraye Viral vectors as tools to model and treat neurodegenerative disorders J. Gene Med. 7 2005 530 539
26. S. Hacein-Bey-Abina, C. Von Kalle, M. Schmidt, M.P. McCormack, N. Wulffraat, P. Leboulch, A. Lim, C.S. Osborne, R. Pawliuk, E. Morillon, R. Sorenson, A. Forster, P. Fraser, J.I. Cohen, G. deSaint Basile, I. Alexander, U. Wintergerst, T. Frebourg, A. Aurias, D. Stoppa-Lyonnet, S. Romana, I. Radford-Weiss, F. Gross, F. Valensi, E. Delabesse, E. Macintyre, F. Sigaux, J. Soulier, L.E. Leiva, M. Wissler, C. Prinz, T.H. Rabbitts, F. Le Deist, A. Fischer, and M. Cavazzana-Calvo LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 Science 302 2003 415 419
27. S.E. Raper, N. Chirmule, F.S. Lee, N.A. Wivel, A. Bagg, G. Gao, J.M. Wilson, and M.L. Batshaw Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer Mol. Genet. Metab. 80 2003 148 158
28. J. Kimmelman Recent developments in gene transfer: risk and ethics Br. Med. J. 330 2005 79 82
29. J.A. Barranger, S.I. Rapoport, W.R. Fredericks, P.G. Pentchev, K.D. MacDermot, J.K. Steusing, and R.O. Brady Modification of the blood-brain barrier: increased concentration and fate of enzymes entering the brain Proc. Natl. Acad. Sci. USA 76 1979 481 485
30. E.A. Neuwelt, J.A. Barranger, M.A. Pagel, J.M. Quirk, R.O. Brady, and E.P. Frenkel Delivery of active hexosaminidase across the blood-brain barrier in rats Neurology 34 1984 1012 1019
31. K. Stewart, O.A. Brown, A.E. Morelli, L.J. Fairbairn, L.S. Lashford, A. Cooper, C.E. Hatton, T.M. Dexter, M.G. Castro, and P.R. Lowenstein Uptake of alpha-(l)-iduronidase produced by retrovirally transduced fibroblasts into neuronal and glial cells in vitro Gene Ther. 4 1997 63 75
32. E.D. Kakkis, A. Matynia, A.J. Jonas, and E.F. Neufeld Overexpression of the human lysosomal enzyme alpha-l-iduronidase in Chinese hamster ovary cells Protein Expr. Purif. 5 1994 225 232
33. E. Kakkis, M. McEntee, C. Vogler, S. Le, B. Levy, P. Belichenko, W. Mobley, P. Dickson, S. Hanson, and M. Passage Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I Mol. Genet. Metab. 83 2004 163 174
34. E.D. Kakkis, M.F. McEntee, A. Schmidtchen, E.F. Neufeld, D.A. Ward, R.E. Gompf, S. Kania, C. Bedolla, S.L. Chien, and R.M. Shull Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I Biochem. Mol. Med. 58 1996 156 167
35. P.A. Day-Lollini, G.R. Stewart, M.J. Taylor, R.M. Johnson, and G.J. Chellman Hyperplastic changes within the leptomeninges of the rat and monkey in response to chronic intracerebroventricular infusion of nerve growth factor Exp. Neurol. 145 1997 24 37
36. K. Yamada, A. Kinoshita, E. Kohmura, T. Sakaguchi, J. Taguchi, K. Kataoka, and T. Hayakawa Basic fibroblast growth factor prevents thalamic degeneration after cortical infarction J. Cereb. Blood Flow Metab. 11 1991 472 478
37. J.G. Nutt, K.J. Burchiel, C.L. Comella, J. Jankovic, A.E. Lang, E.R. Laws, A.M. Lozano, R.D. Penn, R.K. Simpson, M. Stacy, G.F. Wooten, and the ICV GDNF Study Group, Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD, Neurol. 60 (2003) 69-73.